Blue Faery, Liver Cancer and the Promise of New Drugs

In 2007, the first targeted therapy for HCC—Nexavar (sorafenib)—was approved by the Food and Drug Administration (FDA). It took a decade for the next targeted drug, Stivarga (regorafenib), and the first immunotherapy, Opdivo (nivolumab), to be approved.

Read the full article
Previous
Previous

Blue Faery's Patient Community Shares Practical Resources to Help Patients With HCC Manage Their Own Care

Next
Next

New Online Resources Provide Support to the Liver Cancer Community